Alivus Life Sciences working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY24Mar 2024FY23Mar 2023FY22Mar 2022
231.45×231.45×201.64×180.68×
125.67×125.67×125.00×115.78×
1.17×1.55×1.61×1.54×
0.82×0.82×0.84×0.86×
0.88×0.88×0.67×1.43×
0.61×0.61×0.49×0.97×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
30/09/2026
Inventory Days (DIO)180.68201.64231.45231.45
Receivable Days (DSO)115.78125.00125.67125.67
Working Capital Turnover1.541.611.551.17
Asset Turnover0.860.840.820.82
Cash Conversion (CFO/Net Income)1.430.670.880.88
CFO/EBITDA0.970.490.610.61
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.